Author details

Full Name

Baoshan Zhang

Affiliation

ORCID

Career Start Year

2003

Papers

134

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37098956	Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.		2023
37766115	Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes.	Vaccines (Basel)	2023
37738240	Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus.	PLoS Pathog	2023
37989731	Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.		2023
37553406	Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery.	NPJ Vaccines	2023
37345226	Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain.		2023
36909529	An intact amber-free HIV-1 system for in-virus protein bioorthogonal click labeling that delineates envelope conformational dynamics.		2023
37061547	Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles.		2023
37436900	Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.		2023
37436899	HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.	Cell Rep	2023
36931276	Cryo-EM structures of anti-malarial antibody L9 with circumsporozoite protein reveal trimeric L9 association and complete 27-residue epitope.		2023
37295404	Vaccine elicitation and structural basis for antibody protection against alphaviruses.	Cell	2023
36729903	Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.	MAbs	2023
37104089	Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.		2023
35324257	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.	Science	2022
35589938	Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency.	Scientific Reports	2022
36302375	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.	Cell Reports	2022
36344847	Cryo-EM structures of prefusion SIV envelope trimer.	Nat Struct Mol Biol	2022
36284200	Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.	Scientific Reports	2022
35736810	Highly protective antimalarial antibodies via precision library generation and yeast display screening.	Journal of Experimental Medicine	2022
35609088	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.	PLoS ONE	2022
35413243	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site.	Structure	2022
36423012	Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1.	Vaccines	2022
34753907	Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces.	Nat Commun	2021
34020817	A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.	Vaccine	2021
33803622	Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria.	Vaccines	2021
33803302	Single-Shot Vaccines against Bovine Respiratory Syncytial Virus (BRSV): Comparative Evaluation of Long-Term Protection after Immunization in the Presence of BRSV-Specific Maternal Antibodies.	Vaccines	2021
33684923	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.	Nature	2021
33532778	Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.	bioRxiv	2021
33532763	Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.	Res Sq	2021
34210892	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.	Science	2021
34200826	Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography.	Antibodies (Basel)	2021
33826898	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base.	Cell Reports	2021
33655252	Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.	bioRxiv	2021
34135892	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses.	Front Immunol	2021
34328065	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.	mAbs	2021
34244481	Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs.	Nature Communications	2021
33649208	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.	Proc Natl Acad Sci U S A	2021
33494381	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.	Vaccines (Basel)	2021
34461095	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity.	J Biol Chem	2021
34788599	Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.	Immunity	2021
34731616	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies.	Cell Rep	2021
34898670	Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2.	AIChE J	2021
34551978	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.	Proceedings of the National Academy of Sciences of the United States of America	2021
35018379	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.		2021
33271067	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains.	Cell Host Microbe	2020
32268107	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.	Cell Rep	2020
32130953	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.	Cell Host Microbe	2020
32295908	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.	Journal of Virology	2020
32443437	A Single Shot Pre-fusion-Stabilized Bovine RSV F Vaccine is Safe and Effective in Newborn Calves with Maternally Derived Antibodies.	Vaccines	2020